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ABSTRACT 
 
Multiple myeloma (MM) is incurable and invariably becomes resistant to chemotherapy. Although the 
mechanisms remain unclear, hypoxic conditions in the bone marrow have been implicated in 
contributing to MM progression, angiogenesis, and resistance to chemotherapy. These effects occur 
via adaptive cellular responses mediated by hypoxia-inducible transcription factors (HIFs), and 
targeting HIFs can have anti-cancer effects in both solid and hematological malignancies. Here, it 
was found that in most myeloma cell lines tested, HIF1α, but not HIF2α expression was oxygen 
dependent and this could be explained by the differential expression of the regulatory prolyl-
hydroxylase isoforms. The anti-MM effects of a sequence-specific DNA-binding pyrrole-imidazole 
polyamide (HIF-PA), that disrupts the HIF heterodimer from binding to its cognate DNA sequences, 
were also investigated. HIF-PA is cell permeable, localizes to the nuclei, and binds specific regions of 
DNA with an affinity comparable to that of HIF transcription factors. Most of the MM cells were 
resistant to hypoxia-mediated apoptosis, and HIF-PA treatment could overcome this resistance in 
vitro. Using xenograft models, it was determined that HIF-PA significantly decreased tumor volume 
and increased hypoxic and apoptotic regions within solid tumor nodules and the growth of myeloma 
cells engrafted in the bone marrow. This provides a rationale for targeting the adaptive cellular 
hypoxic response of the O2-dependent activation of HIFα using polyamides. 
 
Implications:   
Pyrrole-imidazole (Py-Im) polyamides target and disrupt the adaptive hypoxic responses in MM cells 
that may have clinical significance as a therapeutic strategy to treat myeloma engrafted in the bone 
marrow microenvironment. 
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INTRODUCTION 
 
Multiple myeloma (MM) is an incurable disease of malignant plasma cells characterized by high rates 
of relapse and resistance to drug therapies (1-3). The reasons why this disease is so difficult to cure 
is unclear, but the bone marrow (BM) microenvironment is known to confer critical growth and 
survival advantages that protect tumor cells from apoptosis-inducing stressors (4, 5). The BM is 
hypoxic (p02 ~10-30 mmHg) when compared to most other tissues (pO2 ~85-150 mmHg) (6) and 
paradoxically, while oxygen stress can kill tumor cells (7), low-oxygen conditions also promote tumor 
progression (8), angiogenesis (9), and resistance to chemotherapy (10). These pro-survival 
responses to low oxygen tension are regulated by adaptive cellular responses mediated by several 
oxygen-sensitive transcription factors; the most important of these being the hypoxia-inducible factors 
(HIFs) (for review see (11)). HIFs are composed of a constitutively expressed β-subunit 
(HIF1β/ARNT) and inducible α-subunits (HIF1α, 2α, and 3α) that are responsive to oxygen levels and 
are regulated via proteosome-mediated degradation.  Briefly, under “normoxic” conditions, the HIFα 
subunits are hydroxylated by a number of closely related prolyl-hydroxylase domain proteins (PHD1-
3) that results in recognition of the α-subunit by the von Hippel-Lindau tumor suppressor (VHL), and 
its subsequent ubiquination and rapid degradation by the proteosome. This normally maintains the 
HIFα-subunits at very low levels in the cell. Under hypoxic conditions (pO2 <50 mmHg), the proline-
hydroxylase activity is inhibited and HIFα degradation is not initiated (12).  This allows dimerization of 
the α and β-subunits and the translocation and binding of HIF to the hypoxic response elements 
(HRE), thereby inducing gene transcription of hypoxia related survival and angiogenic factors. 
 
It has been shown that heightened expression of pro-angiogenic factors (such as VEGF) and 
increased microvessel density within myeloma tumors is strongly correlated with disease 
development and progression, as well as being predictive of poor patient prognosis (13-16). This 
provided a rationale for using VEGF-targeting drugs, such as bevacizumab (Avastin), to attempt to 
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inhibit angiogenesis and increase hypoxic stress in MM tumors, although only modest anti-tumor 
effects were observed (17). These results call into question the overall effectiveness of targeting 
angiogenesis as a mono-therapeutic strategy for treating MM in the clinic. Noting that the increase of 
hypoxia within the tumor bed following inhibition of VEGF results in the subsequent activation of the 
adaptive hypoxic response and induction of survival factors may provide an explanation for these 
underwhelming effects. Under this hypothesis, we would argue that these resultant hypoxic conditions 
are actually supportive of MM progression (because low O2 represents a natural component of the 
bone marrow niche in which myeloma engraft) by maintaining hyperactive HIF activity.  Thus, rather 
than killing the tumor cells, inhibition of angiogenesis may actually facilitate a pro-survival adaptive 
hypoxic response through HIF activation.  If true, then targeting the specific HIF-mediated response 
to hypoxia may be a more effective anti-myeloma therapy than targeting VEGF or angiogenesis 
alone.  In fact, there are a number of different hypoxia and HIF targeting strategies currently being 
tested in MM with varying levels of success (18). 
 
In this study, we tested the effects of inhibiting the hypoxic adaptive response using a synthetically 
derived, sequence-specific DNA-binding Py-Im polyamide (PA) composed of the aromatic rings of N-
methylpyrrole and N-methylimidazole amino acids designed to recognize and interfere with HIF 
binding to HRE sequences within the minor grove of the DNA helix (19).  We found that under low 
oxygen culturing conditions, most myeloma cell lines were relatively resistant to hypoxia-mediated 
apoptosis and that HIF1α, but not HIF2α, was upregulated in an oxygen-dependent manner. 
Treatment of MM cells with our HIF-polyamide (HIF-PA) overcame resistance to hypoxia-mediated 
apoptosis in vitro as well as inhibited the transcription of multiple hypoxia-induced genes. We also 
found that combination treatment with HIF-PA polyamides (to inhibit gene transcription) and the 
mTOR inhibitor rapamycin (to inhibit gene translation) was markedly more effective at overcoming 
resistance to hypoxia-mediated apoptosis in MM cells. In additional experiments, we used xenograft 
models to study the anti-MM effects of Py-Im polyamide treatment on MM tumors in vivo and found 
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that Py-Im polyamides were well tolerated by the mice and had a marked anti-tumor effect 
characterized by a significant increase in hypoxia as well as concomitant increases in apoptotic and 
necrotic regions within solid tumor nodules as well as inhibition of myeloma growth in tumors 
engrafted in the BM.  Altogether, these data suggest that sensitivity of myeloma to polyamide therapy 
may be related to the inhibition of gene expression induced by the oxygen-dependent activation of 
HIF1α (but not necessarily HIF2α) and provides a rationale for targeting the adaptive hypoxic 
responses in MM using these compounds. 
 
MATERIALS AND METHODS 
 
Cell lines and reagents:  All cell lines were purchased from ATCC and maintained at 37oC and 5% 
CO2 (“normoxic” condition) unless noted.  The cell lines were validated using the Johns Hopkins 
Genetic Core Research Facility (Baltimore, MD) and stock aliquots were stored under liquid nitrogen. 
Testing for mycoplasma was performed using a mycoplasma PCR detection kit (Sigma-Aldrich, St 
Louis, MO). Py-Im polyamides were synthesized by solid-phase methods on Kaiser oxime resin 
(Nova Biochem, Billerica, MA) (20). The tested polyamide, HIF-PA, targets the sequence 5’-
WTWCGW-3’ (W=A or T) and modulates a subset of hypoxia-induced genes, whilst the control 
polyamide (CO-PA) recognizes the non-HRE sequence 5’-WGGWCW-3’. Enzyme-linked 
immunosorbent assay (ELISA) kits specific for human VEGF was purchased from R&D Systems 
(Minneapolis, MN). The Hypoxyprobe-1 kit was purchased from HPI Inc (Burlington, MA). Cellular 
apoptosis was measured by flow cytometry using a cleaved caspase-3 kit (BD Biosciences, San 
Jose, CA).  Small inhibitory RNA (siRNA) for HIF1α (Silencer Select siRNA ID# s6539, gene ID# 
3091) and scrambled control RNA (Silencer Select negative control #1 siRNA) were purchased from 
Ambion (Grand Island, NY).  Cells were transfected with siRNA using Lipofectamine-2000 (Life 
Technologies, Grand Island, NY). 
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Immunoblots: Protein was isolated and western blot analysis was performed as described previously 
(21).  Nuclear and cytoplasm fractions were isolated using the Thermo Scientific NE-PER™ Nuclear 
and Cytoplasmic Extraction Kit (Rockford, IL) following the manufacturers instruction. HIF1α antibody 
(clone 54/HIF1) was purchased from BD Biosciences. β-tubulin (clone H-235), LaminA/C (clone 
14/LaminAC), BCL-XL (clone H-5), Survivan (clone D-8), BNIP3 (clone ANa40), BCL-2 (clone C-2), 
goat anti-mouse and goat anti-rabbit IgG horseradish peroxidase-conjugated antibodies were 
purchased from Santa Cruz Biotechnology (Dallas, TX). BID (rabbit polyclonal), BAX (rabbit 
polyclonal), AKT-total (clone C67E7), AKT-S473 (clone D9E) and AKT-T308 (clone C31E5E) and the 
P70-total, P70-T421/S424, and P70-T389 antibody kits were purchased from Cell Signaling 
Technology (Danvers, MA).  MCL-1 (clone 542808) was purchased from R&D systems. REDD1 
(clone 1G11) was purchased from Bethyl Laboratories (Montgomery, TX). The EGLN1/PHD2 (rabbit 
polyclonal), EGLN3/PHD3 (mouse polyclonal), EGLN3/PHD3 positive control (an EGLN3/PHD3 over 
expressing lysate from HEK293T cells), HIF2α (rabbit polyclonal), and Factor inhibiting HIF1 (FIH) 
antibodies (clone 162C) were purchased from NOVUS Biologicals (Littleton, CO).  
 
Hypoxia-treatments:  For induction of hypoxia, MM cells were cultured in a humidified Hypoxygen 
hypoxia chamber (Grandpair, Heidelberg, Germany).  Variable pO2 levels were established in the 
hypoxia chamber from 2-0.1% O2, and 5% CO2 at 37 °C. Oxygen levels were regularly tested and 
calibrated using the manufacturer’s protocol. 
 
Generation of hypoxia response element luciferase-expressing (HRE-LUC) cell lines: HRE-LUC 
reporter MM cell lines (8226, U266, OPM-2) were generated by stably transducing cells using the 
Cignal lentiviral kit (Qiagen, Valencia, CA) followed by selection with hygromycin (350 mg/ml). For the 
orthotropic xenograft studies, other luciferase-expressing 8226 cells (8226-LUC) were stably 
transfected with the pGL4.5 luciferase reporter vector (Promega, San Louis Obispo, CA) using an 
AMAXA Nucleofector Kit (Lonza, Koln Germany) followed by selection with hygromycin (350 mg/ml). 
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The in vitro luciferase activity was confirmed and measured using the dual-luciferase reporter assay 
kit (Promega, San Louis Obispo) in a luminometer.  The in vivo luciferase activity was measured 
using the VivoGlo luciferine substrate (Promega). 
 
Real time PCR: Quantitative expression of VEGF was carried out by quantitative real time PCR.  
RNA was isolated using Triazol (Life Technologies, Carlesbad, CA) and cDNA was synthesized using 
cDNA synthesis kit (Life Technologies).  VEGF mRNA was amplified using VEGF primers (Life 
Technologies) in an ABI 7300 real time PCR machine (Life Technologies). The Applied Biosystems® 
TaqMan® Array Human Hypoxia 96-well Plate was used to test for changes in hypoxia signaling 
associated genes. 
 
Animals:  Male NOD/SCID or NOG mice (4-6 weeks old) were obtained from Jackson Laboratories 
(Bar Harbor, ME, USA).  All animal studies were conducted in accordance with protocols approved by 
the Institutional Animal Care and Use Committed (IACUC) of the Greater Los Angeles Veterans 
Administration Healthcare System (GLA-VAHS). 
 
SQ Xenograft Model:  We used the murine myeloma xenograft model of Leblanc et al (22) with 
minor modifications (21).  The 8226 cells (10 X 106 cells/mouse) were mixed with matrigel (BD 
biosciences) then injected subcutaneously into the right flank (200 μl/mouse) of the mice.  The mice 
were monitored and randomized into drug treated or control groups (10 mice/group) when the tumor 
volume reached approximately 300-500 mm3.  The Py-Im polyamide solution was prepared as 
previously described (23). Mice were given HIF-PA injections IP every other day for a total of 5 
injections.  The tumor volume was measured using calipers (width and length) using the formula W2 X 
(L/2) (21, 24) every other day during the course of the experiment. 
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Orthotopic Xenograft Model: 8226-LUC cells were injected (10 X 106 cells/mouse) through the tail 
vein (200 μl/injection). In our initial experiments, the localization of human 8226 myeloma cell lines in 
the bone marrow was determined by two methods: (1) flow cytometry staining of bone marrow 
aspirates from the femurs of mice using FITC labeled anti-human CD45 antibodies (BD Biosciences) 
and (2) immunohistochemistry of femurs using anti-human CD45 antibodies. Real time 8226-LUC 
engraftment in the bone marrow was measured in anesthetized mice given an IP injection of VivoGlo 
luciferin substrate (100 mg/kg mouse) and then monitored for luciferase activity in the skeleton using 
a Perkin-Elmer IVIS XRMS small animal imaging system. Luciferase activity in the skeleton of mice 
challenged with 8226-LUC was typically observed between day +15 and day +20 post challenge. 
Once a positive bioluminescent signal was observed, the animals were randomized into groups (6-8 
animals/group) and were treated with HIF-PA or vehicle control as described above, except a total of 
6 injections were given, rather than 5. The luciferase activity was measured twice/week as described 
above and the change in average radiance (photons/sec/cm2/steradian) was measured and analyzed 
using the LivingImage version 4.4 imaging software.   
 
Immunohistochemistry:  For studies in our SQ model, 24 hours after the last injections, the mice 
were euthanized and the tumor mass was excised.  The tumor was bisected using a razor blade: one 
half of the tumor was immediately placed in 10% buffered formaldehyde overnight, and the other half 
was flash frozen for protein extraction.  Formaldehyde fixed tumors were embedded in paraffin and 
cut into 5 μm-thick serial sections using standard histological procedures. Immunohistochemical 
staining with cleaved caspase 3, and Hypoxyprobe (pimonidazole) (HPI Inc) was conducted using 
standardized automated methods.  
 
Morphometric Analysis:  IHC analysis was performed on tissue sections with a Nikon Microphot-SA 
microscope (Melville, NY, USA) equipped with plan-apochromat lenses (20X and 40X).  A Diagnostic 
Technologies digital camera, model SPOT-RT was used to capture images with a resolution of 1520 
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X 1080 pixels. Fields were selected by reviewing the slides at low power by a researcher (VM) 
blinded to the treatments. Multiple non-overlapping fields were identified for analysis of regions of 
hypoxia/necrosis and apoptotic index at higher powers within these areas of interest. ImageJ software 
(NIH, USA) was used to measure percent of hypoxia stained tumor sections.  Final images for 
publication were prepared using Adobe Photoshop software. 
 
Oncomine Analysis: The expression level of PHD2/EGLN1 and PHD3/EGLN3 genes in normal, 
MGUS and MM tumors were analyzed using Oncomine, a cancer microarray database and web-
based data-mining platform (25).  In order to reduce our false discovery rate, we selected p<0.0001 
as a threshold. We analyzed the results for p-values and fold change of our genes of interest. 
 
Statistics: Data was screened for consistency and quality by both graphical (histograms, scatter 
plots) and analytical methods (descriptive statistics). Variables were analyzed using generalized 
linear models (GLM) such as ANOVA and t-tests. The effect of combining HIF-PA with rapamycin on 
induction of apoptosis was assessed by the median effect method using Calcusyn Software Version 
1.1 (Biosoft, Cambridge, United Kingdom). Combination indices (CI) values were calculated using the 
most conservative assumption of mutually nonexclusive drug interactions. CI values were calculated 
from median results of apoptosis assays. 
 
RESULTS: 
 
Myeloma cell lines are resistant to hypoxia-induced apoptosis in vitro: Because patient MM 
tumor cells specifically engraft within the hypoxic BM microenvironment, we anticipated that patient-
derived MM cell lines would also exhibit resistance to hypoxia-mediated apoptosis in vitro. This was 
confirmed by analyzing the sensitivity of a panel of MM cell lines cultured under various pO2 
concentrations in increments from 2% down to 0.1% O2 and for various time points up to 72 hours. 
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We chose these experimental ranges because these values fell within the actual pO2 ranges reported 
by Spencer et al (6) from in situ measurement in mouse bone marrow. In their study, O2 levels in the 
marrow were found to be <32 mm Hg, but in some bone marrow niches, it could be as low as 9.9 mm 
Hg (or about 1% O2 with a range of 2 - 0.6% measured in the extra-vascular spaces). We found that 
at O2 levels greater than ~1%, only modest cytotoxicity was observed, even when cells were cultured 
out to 72 hours. Only at very low oxygen conditions (i.e. 0.5 - 0.1% O2), did we see significant levels 
of hypoxia-mediated apoptosis of the MM cells tested when compared to the “normoxia-cultured” 
controls. As shown in Fig 1A, 8226 and U266 cell lines were the most resistant to low pO2 (~15-20% 
apoptosis), whilst H929 and MM1.S were intermediately sensitive (~25-35% apoptosis) to hypoxia-
mediated apoptosis (all measured at 72 hours). In contrast, OPM-2 cells were the most sensitive 
(>50% apoptosis) to low O2, and this effect occurred significantly earlier, by 48 hours.  
 
Culturing cells under low pO2 had different effects on the HIFα-subunits expression in the nuclear and 
cytoplasmic fractions of the hypoxia-resistant (8226) and hypoxia-sensitive (OPM-2) cell lines 
cultured under standard normoxic (~22% O2) or hypoxic (0.1% O2) conditions.  As shown in Fig 1B 
(left panel), HIF1α was constitutively expressed in the nuclear fraction of 8226 cells as well as 
significantly upregulated under hypoxic conditions (measured at 24 hours). In contrast to 8226, 
baseline HIF1α was absent in OPM-2 cells, but was strongly induced by low O2 (Fig 1B, right panel). 
On the other hand, HIF2α was constitutively expressed in both 8226 and OPM-2 cells and this was 
independent of O2-levels (Fig 1B). The rapid upregulation of HIF1α in OPM-2 cells was confirmed 
using the hypoxia mimic, CoCl2, which induced HIF1α expression by 1 hour and reached a maximum 
by 18 hours (Fig 1C). A strong O2-dependent induction of HIF1α was also noted in MM1S, H929, and 
U266 cell lines (Fig 1D), while HIF2α expression was independent of O2 levels in H929 and U266 
cells, but not in MM1S cells. These findings are generally similar to other reports describing HIF 
expression in MM cells (3, 26). Low pO2 (0.1% 24hrs) did not affect the expression of the pro-survival 
factor Bcl-2, but did inhibit Bcl-xl and MCL-1 in OPM-2 and 8226, whilst survivin was only 
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downregulated in OPM-2 cells (Fig 1E). Survivin has been reported to play a role in HIF-regulated 
survival of MM and may be an important target for future studies (27). Low pO2 also upregulated the 
pro-apoptotic factors, BNIP3 (a known HIF target) and BID in both lines tested, but BAX was only 
upregulated in OPM-2.   
 
Since we observed differential oxygen-dependent expression patterns for the HIFα-subunits, we next 
asked if expression in the PHD isoforms responsible for regulating the α-subunits could explain these 
results. As seen in Fig 2A, expression of PHD2/EGNL1 was absent in 8226, but strongly expressed in 
OPM-2 cells.  It has been reported that PHD2/EGLN1 preferentially hydroxylates HIF1α (28), and its 
absence would explain why 8226 cells express constitutive HIF1α under normoxic conditions. Along 
similar lines, we also found that PHD3/EGLN3, which preferentially hydroxylates HIF2α (29), was 
absent in both 8226 and OPM-2 cells, and that also explains the oxygen-independent expression of 
HIF2α in both these cell lines.  To ensure that our antibodies could identify PHD/EGLN3 antigens, we 
included a positive internal EGLN3 control (EGLN3 overexpressing lysate from HEK293T cells 
purchased from NOVUS) in our immunoblots. We also found that low pO2 (0.1%) significantly 
upregulated PHD2/EGLN1 protein expression, and probably this likely acts as a negative feedback 
mechanism to return HIF back to basal levels when O2 levels return back to normal (30). 
Furthermore, hypoxia-mediated upregulation of PHD2/EGLN1 was unaffected by treatment with HIF-
PA. We also examined the expression of another O2-dependent regulator of HIF1α, the factor 
inhibiting HIF-1 protein (FIH), and found that there was no difference in expression under either 
normoxic or hypoxic conditions in the cell lines we tested. 
 
To further characterize the expression patterns of PHD2/EGLN1, we used the Oncomine tool, a 
publically available cancer microarray database to query if there were differences in gene expression 
in clinical specimens of MM or monoclonal gammopathy of undetermined significance (MGUS) versus 
normal controls within two data sets; Zhan et al (N=78 samples) (31) and Agnelli et al (N=158) (32).  
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As shown in Figure 2B, PHD2/EGLN1 (top panel) was significantly overexpressed in MM specimens 
versus normal specimens (p<0.05), and in MGUS versus normal specimens in the Zhan study 
(p<0.05) but not in the Agnelli study (p>0.05).  On the other hand, PHD3/EGLN3 (bottom panel) was 
not significantly different in MM and MGUS versus normal specimens (p>0.05) in either data set, 
although there was a general downward trend of expression of this gene. Next, we used the 
TaqMan® Array Human Hypoxia 96-well assay system to analyze for changes in a subset of hypoxia-
related genes in 8226 cells. As shown in Fig 2C, hypoxia increased the relative expression of HIF1α 
by 6 fold, but had only minor effects on HIF2α expression, mirroring the results shown in Fig 1B.  
Other genes associated with the HIF regulatory pathway, such as PHD2/EGLN1, cullen-2 and EP300, 
were induced, whilst PHD3/EGLN3 and E3 ubiquitin were downregulated and which mirrored the 
results from Fig 2A and 2B above. Not unexpectedly, VEGF and angiopoieitin-4 gene expression, 
genes that are well known to be sensitive to hypoxia, were upregulated by hypoxia. 
 
HIF-targeting polyamide (HIF-PA) inhibits the adaptive hypoxic response in MM cells: We next 
tested the ability of HIF-PA to inhibit the cellular response to hypoxia using 8226 cells that had been 
stably transduced with a hypoxia response element (HRE)-luciferase reporter construct (8226-HRE-
LUC). As shown in Fig 3A, culturing 8226-HRE-LUC cells under low pO2 (0.1% O2, 24hr) resulted in a 
~2 fold induction of luciferase activity over the baseline “normoxic” controls.  This hypoxia-mediated 
LUC induction was significantly inhibited (p<0.05) by treatment with HIF-PA but not by a control 
polyamide (CO-PA) that recognized a non-HRE sequence. To provide further support for our model, 
we knocked down HIF1α expression in 8226-LUC cells using HIF1α siRNA (Fig 3B top panel). As we 
expected, and as shown in Fig 3B (bottom panel), the hypoxia-mediated increase of LUC activity in 
8226-LUC reporter cells transfected with HIF1α siRNA also demonstrated a significant inhibition of 
the hypoxia-induced LUC activity. These data support our hypothesis that HIF-PA can specifically 
inhibit the HIF-mediated cellular response to hypoxia in 8226 cells.  Next we showed that HIF-PA 
could inhibit the expression of HIF-mediated gene expression using real-time PCR to assay for the 
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effect of HIF-PA treatment on the expression VEGF RNA. It is well known that hypoxia upregulates 
VEGF transcription in myeloma cells, and as expected, culturing 8226 cells under hypoxic conditions 
(0.1% O2, 24 hrs) induced VEGF mRNA by ~3-4 fold (Fig 3C). Treatment with HIF-PA significantly 
(p<0.05) inhibited this hypoxia-mediated upregulation of VEGM mRNA in a dose dependent manner. 
This effect on mRNA was also mirrored by HIF-PA mediated inhibition of VEGF protein (measured by 
ELISA) in the supernatant of these cells (Fig 3D). Altogether, these data demonstrate that HIF-PA 
specifically and effectively inhibits the adaptive hypoxic response in MM cells. 
 
HIF-PA treatment overcomes MM cell resistance to hypoxia: We next asked if inhibiting the 
hypoxic response with HIF-PA could sensitize a panel of MM cells to hypoxia-mediated killing. We 
assayed this using hypoxia resistant 8226 and U266 cells and hypoxia sensitive MM1.S and OPM-2 
cells that were cultured under normoxic or hypoxic conditions (0.1% O2) in the presence of HIF-PA or 
a control polyamide (CO-PA). HIF-PA had little effect on 8226 cells (Fig 4A) and U266 (Fig 4B) 
cultured under standard conditions (white bars), but the treatment of 8226 and U266 cells cultured 
under hypoxic conditions resulted in significant and dose-dependent hypoxia-mediated killing (an 
increase from ~20% to ~60%) (black bars) (ANOVA *p<0.05). The hypoxia “sensitive” MM1.S and 
OPM-2 cells (Fig 4C and D) were even more responsive to HIF-PA, (ANOVA *p<0.05) with a similar 
increase in apoptosis observed by only 24 hrs when cultured under low O2 conditions. The CO-PA 
compound had little, if any, effect on the hypoxia-mediated apoptosis in any of the cell lines 
examined. These data support our hypothesis that inhibiting the adaptive hypoxic response with HIF-
PA overcomes MM resistance to hypoxia-mediated apoptosis in vitro. 
 
As an in vivo correlate of the above in vitro data, we tested HIF-PA activity using a xenograft SQ MM 
tumor model in NOD/SCID mice (21, 24, 33).  The mice were challenged on the flank with 10 X106 
8226 cells admixed with matrigel.  Once a palpable tumor developed (~15 days later), the mice were 
randomized into groups (N=10 mice/group) to be given 5 IP injections of either HIF-PA (100 
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nmol/injection) or vehicle control every other day (Fig 5A, arrows on X-axis indicate days of 
treatment). The HIF-PA treatments were well tolerated, with only a small transient decrease in weight 
being observed, and induced a rapid and significant inhibition of tumor growth in the HIF-PA-treated 
mice compared to control mice (p<0.05). In order to confirm uptake of HIF-PA, we treated an 
additional group of mice (N=2 mice/group) with a FITC-conjugated HIF-PA and measured drug 
uptake by real-time fluorescent imaging. We observed some auto-fluorescence signal in the bladder 
and gut (Supplemental Figure 1A, mice #1 and #2). However, in FITC-HIF-PA treated mice, positive 
signals were also observed in the tumor nodules (Supplemental Figure 1A, note arrow indicating 
tumor nodule in mouse #3 and #4). Labeled HIF-PA localization in the nuclei was confirmed by 
fluorescent confocal microscopy of excised tumor sections, costained with DAPI (Supplemental 
Figure 1B). This is consistent with the recent studies on the uptake C14 labeled Py-Im polyamides into 
tumors (34) 
 
In order to characterize the in vivo effect of HIF-PA, we excised the tumor nodules 24 hrs after the 
last injection and performed immunohistochemistry on serial sections stained either for hypoxia 
(pimonidazole staining, left panels) or apoptosis (cleaved caspase 3, right panels) (Fig 5B).  Both 
vehicle control (top left panel) and HIF-PA (bottom left panel) treated tumors had regions of hypoxia 
(brown stained areas), but the extent of hypoxia was significantly greater in the HIF-PA treated 
tumors than in the control tumors (quantified in Fig 5C). We also noted there were significantly 
greater areas of necrosis within the tumor bed in HIF-PA treated tumors compared to control tumors 
as well as a strong physical correlation between areas of hypoxia and presence of apoptosis in the 
HIF-PA-treated tumors (see Fig 5B, bottom right panel). In contrast, apoptotic cells were evenly 
distributed throughout the tumor bed in the control tumors (Fig 5B, top right panel) and were not 
localized to a specific geographic region in the tumor. As shown in Fig 5C, we found that the area of 
positive hypoxia staining in tumor sections (10 tumors/group, 10 fields/tumor) was ~35% in nodules 
harvested from the HIF-PA treated mice, compared to about 18% in the tumors harvested from mice 
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treated with vehicle control (p<0.05). The apoptotic index (AI) in both the normoxic or hypoxic regions 
of the tumor was determined by counting number of apoptotic cells in these regions using 
corresponding serial sections (10 tumors/group, 10 fields/region) stained with pimonidazole to identify 
the specific geographical regions of interest. As shown in Fig 5D, there was an approximate 3-4 fold 
increase in apoptotic cells located within the hypoxic regions of tumors from the HIF-PA treated mice 
compared to hypoxic regions of the control tumors (P<0.05), whilst there was no difference in 
apoptotic index within “normoxic” regions of the tumor bed.  Finally, we examined the expression of 
VEGF in tumor lysates by ELISA (Fig 5E).  As with our in vitro data (see Fig 3D), HIF-PA significantly 
inhibited VEGF expression by approximately 50% when compared to control tumors.  Altogether, this 
data supports our hypothesis that HIF-PA can overcome resistance to hypoxia-mediated apoptosis in 
vivo by inhibiting the adaptive hypoxic response.  
 
As a more physiologically relevant model, we developed an orthotopic, “disseminated” bone marrow-
engrafted xenograft model based on the model developed by Miyakawa (35) using LUC2-transfected 
8226 (these cells use a different p4.5 LUC2 plasmid to drive luciferase expression and thus are 
different than the 8226-HRE-LUC cells described above) allowing us to perform real-time longitudinal 
studies on myeloma tumors engrafted in the BM. As shown in Supplemental Fig 1A, NOG mice 
challenged with 8226LUC cells developed bone marrow engrafted MM tumors that could be observed 
by bioluminescence (top panel) and X-ray (bottom panel) analysis. Approximately 20-50% of the bone 
marrow cells from inoculated mice were positive for human CD45 confirmed by flow cytometry using 
FITC-conjugated anti-huCD45 antibody (Supplemental Fig 2B) and by IHC of in situ huCD45+ 8226 
cells in the mouse femurs (Supplemental Fig 2C). Gross histological analysis of the mice didn’t show 
tumor formation in other tissues (i.e. liver, lung, spleen, or kidney). 
 
We then asked if treatment with HIF-PA had an anti-MM effect on tumor cells in the bone marrow. As 
shown in Fig 6A, approximately +20 days post challenge with 8226-LUC cell, engraftment of LUC2+ 
on February 1, 2016. © 2016 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 22, 2016; DOI: 10.1158/1541-7786.MCR-15-0361 
cells in the skeleton was confirmed and the mice were then randomized into treatment groups (6-8 
mice/group). The mice were then give IP injections of 100 nmol/injection of HIF-PA every other day 
(arrows indicate days of injection on day +27, +29 +31, +34, +36 and +38) or vehicle control. The 
average radiance (photons/sec/cm2/steradian) was measured at various time points using a Perkin 
Elmer Lumina XRMS small animal imager (out to day +40). The treatment with HIF-PA significantly 
inhibited MM tumor growth in the marrow (data is presented as average radiance ± 95% confidence 
intervals) starting after the third injection and reaching statistical significance by the last HIF-PA 
injection on day +38). It should be noted that this particular HIF-PA treatment regimen was not able to 
delay the development of hind limb paralysis (the main end point criteria) when compared to control 
animals, with ~50% of the animals reaching their end point on day +59 (control mice) and day +62 
(HIF-PA treated mice).  Representative images of some of the mice are shown for day +22, +35 and 
+40.  We noted a decrease in the luciferase activity as well as a general shrinkage of individual tumor 
foci in the mice. Specifically, in control mice, tumor foci tended to grow and merge over time, while in 
HIF-PA treated mice, the foci remain relatively small and isolated. 
 
Effect of targeting the mTOR pathway on regulation of HIF-PA sensitivity: Since we have 
previously demonstrated that mammalian target of rapamycin (mTOR) inhibitors kill MM cells in vivo, 
and this anti-MM effects is mediated, at least in part, by inhibiting VEGF translation and de novo 
angiogenesis (21, 24, 33, 36), we asked if there would be a synergistic effect if we combined HIF-PA-
mediated inhibition of hypoxia-inducible gene transcription in combination with rapamycin-mediated 
inhibition of mTOR-mediated regulation of protein translation. As shown in Fig 7A, treatment of 8226 
cells with the mTOR inhibitor rapamycin had a modest effect on apoptosis in MM cells cultured under 
normoxic or hypoxic conditions (0.1% O2, 72 hours). However, under low pO2 conditions, using 
median effect combination indices (CI) analysis for apoptosis induction, we found that the 
combination treatment with rapamycin and HIF-PA resulted in synergistic drug interactions with CI 
values <1 across several concentrations tested. Altogether, this suggests that targeting both 
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transcription and translation of hypoxia-induced genes may be an effective anti-MM strategy (Fig 7A 
see grey and black bars and bracketed area). We also asked if REDD1, a hypoxia-sensitive negative 
regulator of mTOR, was affected by low pO2 in both 8226 and OPM-2 cells. As shown in Fig 7B, 
REDD1 was strongly induced in MM cells.  Furthermore, the functional effects of hypoxia on mTOR 
signaling demonstrated a marked inhibition of phosphorylation of p70S6 kinase but only modest 
effects on AKT phosphorylation.  The effects of hypoxia-mediated inhibition on p70 was transient and 
reversible in OPM-2 cells, with p70 (389) phosphorylation levels rapidly returning to normal within 2 
hrs following reoxygenation of the cells (Fig 7C).  
 
Discussion: 
 
There is increasing evidence that low oxygen conditions are supportive of MM growth, progression 
and the development of resistance to chemotherapy, and that this occurs via a cellular adaptive 
hypoxic response mediated, at least in part, by the action of HIF-transcriptional factors. Because of 
this and the development of more resistant tumor phenotypes associated with hypoxia, there has 
been increasing interest in targeting HIF-mediated gene transcription to overcome these effects (18). 
Hypoxia induces the expression of about ~100-200 genes mostly related to metabolism, 
angiogenesis, and apoptosis (37, 38), and in this study, we found that a sequence-specific DNA-
binding oligomer (HIF-PA) that is capable of binding to the HRE and inhibiting HIF-mediated gene 
transcription (19, 39) can overcome MM resistance to hypoxia-mediated apoptosis in vitro and in vivo.  
We also found that treating MM cells with a combination of HIF-PA, to inhibit gene transcription, and 
rapamycin, to inhibit gene translation, had a strong synergistic cytotoxic effect against MM tumor cells 
cultured under hypoxic conditions. Our results provide a strong pre-clinical rationale for using 
polyamides to target the adaptive hypoxic response in MM and may prove to be efficacious in treating 
myeloma tumors engrafted in the hypoxic bone marrow microenvironment.  We also note that the 
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ability of HIF-PA to recognize and bind to HRE sequences enables them to block both the 
HIF1α/HIF1β and HIF2α/HIF1β dimers. 
 
We surveyed a panel of MM cell lines and found that the expression of the HIF1α-subunit was 
generally absent under normal culturing conditions but was rapidly increased by low pO2 levels. The 
exception to this was 8226 cells, which constitutively expressed HIF1α under normoxic conditions, 
although it was further upregulated by hypoxia. In contrast to the HIF1α-subunit, HIF2α was 
constitutively expressed in all the cell lines studied (except MM1S), and the expression levels were 
independent of O2 levels.  Of note, we did not observe a correlation between the expression of the 
HIF1α-subunit and sensitivity to hypoxia-mediated cytotoxicity in the cells we examined. These 
results are interesting because they suggest that the HIFα-subunits are differentially regulated by low 
pO2 levels in MM cells and that mechanisms other than just the expression of HIF1α regulates 
sensitivity to hypoxia. In fact, despite their similarities, it is known that the α-subunits can mediate 
different responses to hypoxia and tumorogenesis: HIF1α acts as a tumor suppressor gene and 
inhibits tumor growth, whilst HIF2α acts as an oncogene and promotes tumor growth (3, 40). It has 
also been demonstrated that the different α-subunits have varying affinities for hydroxylation by the 
different PHD isoforms, with PHD2/EGLN1 showing the highest affinity for HIF1α (28) and 
PHD3/EGLN3 showing the highest affinity for HIF-2α (29). In our study, we found that the expression 
patterns of PHD/EGLN isoforms could explain HIFα-subunit expression in both 8226 and OPM-2 
cells. Specifically, PHD2/EGLN1 was expressed at very low levels in 8226, but not in OPM-2, which 
can explain why HIF1α was constitutively expressed in the former but not the later.  It is also likely 
that the absence of PHD3/EGLN3 in MM cells results in the inability to hydroxylate HIF2α, thereby 
rendering its expression independent of O2 levels. Thus, it is likely that the expression and ability of 
PHD isoforms to regulate the expression of the different α-subunits may have important ramifications 
for disease progression and pathology in MM, such as what is observed in patients with VHL-cancer 
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syndrome (41).  In support of this, PHD3/EGLN3, but not PHD2/EGLN1 silencing has been reported 
at a relatively high frequency for patients with MM, Waldenström’s macroglobulinaemia and 
monoclonal gammopathy of undetermined significance and that these patients have a poorer 
prognosis (42) suggesting that PHD/EGLN activity is as important as HIF activity in regulating the 
adaptive hypoxic responses in MM, and is something that we will pursue in future experiments.   
 
There is a dynamic physiological process that exists between the metabolic needs of tumor cell 
growth and the sufficiency of the vascular networks that are required to support these needs. On one 
hand, the development of oxygen stress within the tumor inhibits cell division and growth and induces 
cell death, but on the other hand, hypoxia activates the HIF-mediated cellular responses that provide 
protective growth and survival advantages and that can foster the development of tumor resistance to 
radiation and chemotherapy (27, 43). In this study, we found that HIF-PA was well tolerated by mice, 
localized to the nuclei of the tumor xenografts, and could inhibit tumor growth. Histological analysis of 
HIF-PA treated SQ xenografts indicated that tumor cytotoxicity was remarkably co-localized with 
regions of ischemic stress in the tumor nodules and that VEGF expression was significantly inhibited. 
While VEGF is clearly a factor in the induction of the HIF-PA-mediated killing of MM tumor cells, we 
believe that VEGF is probably only one of many genes affected by targeting the adaptive hypoxic 
response using HIF-PA (39). While our SQ model demonstrated some efficacy of HIF-PA in reducing 
solid MM xenograft tumors, we recognize that this particular model may not be physiologically 
relevant to clinical myeloma, which engrafts in the bone marrow.  Therefore, we also present data 
using an orthotopic MM xenograft model.  In this model, 8226 tumor cells localized to the mouse BM 
demonstrate a similar anti-tumor response to HIF-PA treatment that mirrored the effects seen in our 
SQ model. Specifically, we noted a decrease in luciferase activity measured by the change in 
average radiance, as well as a general decrease in the size of the MM tumor foci engrafted in the 
bone marrow. While HIF-PA had a statistically significant effect on orthotopic MM tumors, this did not 
translate to a longer survival in the mice. We believe that this may be because our initial HIF-PA 
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treatment strategy was not the most effective dosing regimen for establishing and maintaining long 
term anti-myeloma responses in our orthotopic model. For example, HIF-PA availability and 
clearance in the bone marrow still needs to be established. This, in fact, has important ramifications 
for addressing the known limitations of these anti-angiogenesis therapies (44), because HIF-PA 
directly targets the hypoxic response at the level of gene transcription, rather than targeting a single 
downstream effector of hypoxia, such as VEGF. 
 
Because of our previous in vivo studies (21, 24, 33, 36) that demonstrated a correlation between the 
anti-angiogenic effects of the mTOR inhibitor, temsirolimus, we initially hypothesized that hypoxic 
stress alone would be sufficient to kill MM cells.  However, we found that MM cell lines are generally 
resistant to low O2, suggesting that hypoxia-induced physiological stress alone cannot fully explain 
our results. In fact, myeloma cells that are the most resistant to mTOR inhibition (e.g. 8226 and 
U266), are also the most the resistant to hypoxia, whilst cells that are more sensitive to rapalogs, 
such as OPM-2 are the most sensitive hypoxia-mediated killing (45).  It is also known that hypoxia 
regulates the activity of mTOR via the induction of REDD1 (46) although the relationship between 
hypoxia, mTOR activation, and HIF expression/activation remain complex and is not fully understood 
(47).  This is further confounded by the presence of cap-independent, IRES-mediated translational 
pathways (48, 49) that may allow tumor cells to escape mTOR-targeting therapies. Interestingly, we 
find that the combination of polyamides and rapamycin can effectively synergize with each other to 
overcome resistance to hypoxia-mediated killing of 8226 cells in vitro. Along another line of 
reasoning, we noted that in a recent study by Maiso et al (10), hypoxic conditions conferred a striking 
resistance to bortezomib-mediated apoptosis in MM cell lines and, critically, inhibiting HIF1α 
expression could restore sensitivity. If true, then we hypothesized that HIF-PA would likely have a 
similar effect in bortezomib-treated cells by inhibiting the adaptive hypoxic response and overcoming 
any hypoxia-mediated resistance to this drug. However, despite our best efforts, we were unable to 
replicate this phenomenon, and instead found that our results were more similar to those reported by 
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Hu et al (50) which found instead that bortezomib killed MM cell lines cultured under hypoxic 
conditions. It is unclear why our experiments differed from those of Maiso et al, but could reflect 
variations in how hypoxic conditions were established.  Therefore, at least in our hands, it remains to 
be shown if hypoxia confers resistance to chemotherapeutic drugs and if HIF-PA can overcome and 
sensitize MM cells by inhibiting HIF-activity. 
 
In summary, HIF and related hypoxic response factors are frequently upregulated in MM tumors, and 
has been implicated in contributing to the development and prognosis of MM (15). The induction of 
pro-angiogenic, proliferative, metastatic, and glycolytic genes by HIF1 may also be involved in the 
development of chemotherapy resistant phenotypes (10, 27).  In this sense, HIF1, and in particular 
the expression of the different α-subunits, may play dual roles in the survival and progression of MM, 
through the differential α-subunit expression patterns and the genes that they activate. Thus, we 
argue that understanding the role and mechanisms HIF1-mediated adaptive hypoxic response at the 
level of HIF1/DNA binding could be clinically relevant for developing novel therapies against patient 
MM engrafted in the hypoxic bone marrow environment. 
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Figure Legends 
Figure 1.  Cytotoxic effects of low pO2 levels on myeloma cell lines.  (A) The % apoptosis (measured 
by cleaved caspase 3) following 72 hour culture of myeloma cells under “normoxic” conditions (~22% 
O2, 5% CO2) or hypoxic (0.1% O2, 5% CO2) conditions, except for OPM-2 cells which were cultured 
for 48 hours. Brackets indicate P<0.05 (T-test). Values represent mean ± 1 standard deviation of 4 
independent experiments/cell line. (B). Immunoblots of HIF1α and HIF2α-subunit expression in 8226 
and OPM-2 cells cultured under normoxic or hypoxic conditions (0.1% O2, 5% CO2) for 24 hours.  The 
cells were harvested on ice then the cytoplasmic and nuclear fractions were isolated, and the lysate 
was immunoblotted for indicated proteins. C=cytoplasm fraction, N=nuclear fraction. The data 
presented are a representative immunoblots of at least 2 independent experiments.  (C) Time course 
of CoCl2-mediated induction of HIF1α expression in OPM-2 cells.  Cells were cultured with 100nM 
CoCl2 or vehicle control and the cellular lysates were harvested at indicated time points and 
immunoblotted for HIF1α expression. The data presented are a representative immunoblots of at 
least 2 independent experiments. (D) Hypoxia-mediated induction of HIF1α and HIF2α in MM1S, 
H929 and U266 myeloma cell lines cultured under normoxic or hypoxic (0.1% O2, 5% CO2) conditions 
for 24 hours.  Cells were harvested on ice and the cell lysate was immunoblotted for HIF1α and 
HIF2α. The data presented are a representative immunoblots of at least 2 independent experiments. 
(E) Immunoblots showing hypoxia-mediated changes in survival-related protein expression in 8226 
and OPM-2 cells cultured under normoxic or hypoxic conditions (0.1% O2, 5% CO2) for 24 hours.  The 
cells were harvested on ice and the lysate was immunoblotted for indicated proteins. The data 
presented are a representative immunoblots of at least 2 independent experiments. 
 
Figure 2. There is differential expression of HIF regulatory pathway in 8226 cells. (A) Immunoblots of 
PHD2/EGLN1, PHD3/EGLN3 and FIH in 8226 cultured under normoxic or hypoxic conditions (0.1% 
O2, 5% CO2)  for 48 hours in the presence or absence of HIF-PA (10 µM). Cells were harvested on 
ice and the cell lysate was immunoblotted.  A positive immunoblot control (an over expression lysate 
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from HEK293T cells) for PHD3/EGLN3 is included. The data presented are a representative 
immunoblots of at least 2 independent experiments. (B) Boxplot results showing a meta-analysis of 
PHD2/EGLN1 and PHD3/EGLN3 in normal bone marrow, monoclonal gammopathy of undetermined 
significance (MGUS), multiple myeloma, smoldering myeloma and plasma cell leukemia.  Analysis 
was performed using Oncomine and includes two data sets: Angelli et al (N=156) and Zhan et al 
(N=78). (C) Relative fold change in hypoxia-mediated expression of select genes compared to 
normoxic conditions. The 8226 cells were cultured under normoxic or hypoxic (0.1% O2, 5% CO2) 
conditions for 24 hours. The RNA was collected and gene expression was determined by quantitative 
real-time PCR analysis. The relative fold change in hypoxia-mediated gene expression compared to 
normoxic levels are shown. Values above the dotted line indicate upregulation of genes by hypoxia, 
and values below the dotted line indicate downregulation of genes by hypoxia.  These data are 
representative of 2 independent experiments. 
 
Figure 3.  HIF-PA polyamide inhibits the in vitro response to low pO2 in 8226 myeloma cell lines.  (A) 
8226-HRE-LUC reporter cells were cultured under normoxic or hypoxic (0.1% O2, 5% CO2) conditions 
and treated with either 10 µM HIF-PA or 10 µM CO-PA for 24 hours.  Luciferase activity in cell 
extracts was measured using a luminometer. Values are presented as means ± 1 standard deviation 
of 3 independent experiments. Bracket with *=P<0.05 (ANOVA). Bracket with NS= not significant. (B) 
8226-HRE-LUC reporter cells were co-transfected with HIF1α siRNA or scrambled (sc) control and 
were then cultured under normoxic or hypoxic (0.1% O2, 5% CO2) for 24 hours. Luciferase activity in 
cell extracts was measured using a luminometer. Values are presented as means ± 1 standard 
deviation of 3 independent experiments. Bracket with *=P<0.05 (ANOVA). Bracket with NS= not 
significant. Top panel:  Immunoblot demonstrating knockdown of HIF1α (but not HIF2α) by siRNA. 
These data are representative of 3 independent experiments.  Bottom panel: Change in LUC activity 
in treated 8226 cells. Values are presented as means ±1 standard deviation of 3 independent 
experiments. Bracket with *=P<0.05 (ANOVA). Bracket with NS= not significant. (C) HIF-PA (10 µM)-
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mediated inhibition of VEGF mRNA levels in 8226 cells cultured under normoxic or hypoxic (0.1% O2, 
5% CO2) conditions for 24 hours. VEGF mRNA levels were measured by quantitative real-time PCR 
of 3 independent experiments.  *P<0.05. (ANOVA). (D).  Effect of HIF-PA treatment on VEGF protein 
in supernatants of 8226 cells cultured under normoxic or hypoxic conditions were measured by 
ELISA.  Values are presented as mean ± 1 standard deviation of 3 independent experiments. *P<0.05 
(ANOVA). 
 
Figure 4.  HIP-PA treatment sensitizes the hypoxia-resistant 8226, U266, and hypoxia-sensitive 
MM1S and OPM-2 cells to hypoxia-mediated apoptosis in vitro. (A) 8226 were cultured under 
normoxic or hypoxic (0.1% O2, 5% CO2) conditions with indicated concentration of HIF-PA or CO-PA 
for 72 hours. (B) U266 were cultured under normoxic or hypoxic (0.1% O2, 5% CO2) with indicated 
concentration of HIF-PA or CO-PA for 72 hours. (C) MMI.S cells were cultured under normoxic or 
hypoxic (0.1% O2, 5% CO2) with indicated concentration of HIF-PA or CO-PA for 48 hours. (D) OPM-
2 cells were cultured under normoxic or hypoxic (0.1% O2, 5% CO2) with indicated concentration of 
HIF-PA or CO-PA for 24 hours. At the end of the treatment, cells were harvested and the percent 
apoptosis was measured by flow cytometry for cleaved caspase 3.  Values are mean ± 1 standard 
deviation of 3 independent experiments.  Bracket * indicates significant change (P<0.05) (ANOVA) of 
treatment compared to control. 
 
Figure 5.  HIF-PA (100nmol/kg mouse) inhibits 8226 tumor growth in a subcutaneous (SQ) myeloma 
xenograft model (N=10 mice/group). (A) Change in 8226 tumor volume in HIF-PA-treated NOD/SCID 
mice.  Mice were challenged SQ with 10X106 cells admixed in matrigel.  When the tumor volume was 
~500 mm3 (~day 15 post challenge), the mice were randomized into treatment and control groups (10 
mice/group). The mice were given 5 IP injections at indicated concentration (Arrows indicate days of 
treatment) and the tumor volume was measured using calipers. Values represent mean volume ± 
95% confidence interval. *P<0.05. (B) Photomicrographs of SQ tumor sections harvested from mice 
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treated with HIF-PA or vehicle-control treated mice (N=10 mice/group).  Tumors were harvested 24 
hours after last the IP injections.  Serial tumor sections were stained for hypoxia (by pimonidazole; 
brown stained areas) or apoptosis (cleaved caspase 3).  *Indicate corresponding geographic regions 
in the sections.  Arrow indicates areas of hypoxia and associated apoptosis. (C) The percent area of 
hypoxic tumor bed measured by staining with pimonidazole (measured in 10 fields/tumor, 10 
tumors/group) in 8226 tumors harvested from HIF-PA or vehicle-treated mice. Area was measured 
using Metamorph computer software. Values are presented as mean ± 1 standard deviation. *P<0.05. 
(ANOVA)  (D) Apoptotic index (the number of apoptotic cells/unit area) was measured by counting 
cells staining for cleaved caspase 3 (10 fields/tumor, 10 tumors/group). The apoptotic index in regions 
of “normoxia” or “hypoxia” were assayed by using serial sections stained with pimonidazole to identify 
specific geographical areas in the tumor nodules. Values are presented as mean ± 1 standard 
deviation. *P<0.05 (ANOVA). (E) Tumor lysate was collected and VEGF was analyzed by ELISA (10 
tumors/group). Values are presented as mean ± 1 standard deviation. *P<0.05 (T-test). 
 
Figure 6. HIF-PA (100nmol/kg mouse) inhibits 8226-LUC tumor growth in an orthotopic myeloma 
xenograft model (N=8 mice/group). (A) Change in average radiance (p/sec/cm2/ser) in HIF-PA-treated 
NOG mice was measured using IVIS XRMS small animal imaging system.  Briefly, mice were 
challenged IV with 10X106 cells and engraftment of 8226-LUC cells were confirmed by IP injection of 
luciferin substrate (VivoGlo, Promega) starting ~day 20 post challenge.  Once a positive signal was 
observed in the bone marrow, the mice were randomized into treatment and control groups (6-8 
mice/group). The mice were given 6 IP injections at indicated concentration (Arrows indicate days of 
treatment) and the change in average radiance of tumor foci were measured as described above. 
Values represent mean volume ± 95% confidence interval. *P<0.05. (B) Representative images of 
mice imaged on day +22, +35 and +40 showing changes in LUC activity.  Mice were imaged using a 
IVIS XRMS small animal imaging system. 
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 Figure 7.  Combination of rapamycin and HIF-PA can overcome resistance to hypoxia-mediated 
apoptosis in 8226 cells. (A) 8226 cells were cultured under normoxic (22%O2, 5% CO2) or hypoxic 
(0.1% O2, 5% CO2) and treated with the indicated concentrations of rapamycin, HIF-PA or both for 24 
hours. At the end of the treatment, cells were harvested and % apoptosis was measured by flow 
cytometry for cleaved caspase 3.  Values are mean ± 1 standard deviation of 3 independent 
experiments.  Bracket * indicates significant change (P<0.05) of treatment compared to control 
(ANOVA). The effect of combining HIF-PA with rapamcyin on induction of apoptosis was assessed by 
the median effect method using Calcusyn Software Version 1.1 (Biosoft, Cambridge, United 
Kingdom). Combination indices (CI) values were calculated using the most conservative assumption 
of mutually nonexclusive drug interactions. CI values were calculated from median results of 
apoptosis assays. (B) Immunoblots of mTOR-related signaling proteins in 8226 and OPM-2 cells 
cultured under normoxic or hypoxic conditions for 24 hours. The data presented are a representative 
immunoblots of at least 2 independent experiments. (C) Time course of p70S6 kinase 
phosphorylation in OPM-2 cells following re-oxygenation. Cells were cultured under hypoxic 
conditions (0.1% O2, 5% CO2) for 24 hours, then cultured under normoxic conditions (22% O2, 5% 
CO2).  Cell lysates were harvested at indicated time points and immunoblotted for HIF1α and 
phospho-P79S6K (389) expression. The data presented are a representative immunoblots of at least 
2 independent experiments. 
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